CN Patent
CN104095854A — Dpp iv 抑制剂的用途
Assigned to Boehringer Ingelheim International GmbH · Expires 2014-10-15 · 12y expired
What this patent protects
本说明书公开了选定DPP IV抑制剂治疗生理功能性病症及降低风险患者群体发展这些功能性病症的风险的用途。此外,本说明书海公开了上述DPP IV抑制剂组合其它药物的用途,由此可实现升高的治疗结果。所述用途可用以制备相应的药物。
USPTO Abstract
本说明书公开了选定DPP IV抑制剂治疗生理功能性病症及降低风险患者群体发展这些功能性病症的风险的用途。此外,本说明书海公开了上述DPP IV抑制剂组合其它药物的用途,由此可实现升高的治疗结果。所述用途可用以制备相应的药物。
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.